TABLE 6.
KEEG pathway enrichment of C21 steroidal saponins anti-NSCLC.
| Pathway | Count | P Value | Protein |
|---|---|---|---|
| Pathways in cancer | 13 | 0.000000 | BRAF,BCL2,MDM2,EGFR,IGF1R,MAPK8,PIK3CA,PIK3CB,PTGS2,PRKCA,STAT3,SLC2A1,VEGFA |
| HIF-1 signaling pathway | 9 | 0.000000 | BCL2,EGFR,IGF1R,PIK3CA,PIK3CB,PRKCA,STAT3,SLC2A1,VEGFA |
| Pancreatic cancer | 7 | 0.000000 | BRAF,EGFR,MAPK8,PIK3CA,PIK3CB,STAT3,VEGFA |
| Glioma | 7 | 0.000000 | BRAF,MDM2,EGFR,IGF1R,PIK3CA,PIK3CB,PRKCA |
| Epstein-Barr virus infection | 8 | 0.000000 | BCL2,MDM2,ITGAL,ICAM1,MAPK8,PIK3CA,PIK3CB,STAT3 |
| Proteoglycans in cancer | 9 | 0.000000 | BRAF,MDM2,EGFR,IGF1R,PIK3CA,PIK3CB,PRKCA,STAT3,VEGFA |
| Focal adhesion | 9 | 0.000000 | BRAF,BCL2,EGFR,IGF1R,MAPK8,PIK3CA,PIK3CB,PRKCA,VEGFA |
| Rap1 signaling pathway | 9 | 0.000000 | BRAF,EGFR,IGF1R,ITGAL,ITGB2,PIK3CA,PIK3CB,PRKCA,VEGFA |
| FoxO signaling pathway | 8 | 0.000000 | BRAF,MDM2,EGFR,IGF1R,MAPK8,PIK3CA,PIK3CB,STAT3 |
| Prostate cancer | 7 | 0.000000 | BRAF,BCL2,MDM2,EGFR,IGF1R,PIK3CA,PIK3CB |
| MicroRNAs in cancer | 9 | 0.000000 | ABCB1,BCL2,MDM2,EZH2,EGFR,PTGS2,PRKCA,STAT3,VEGFA |
| Natural killer cell mediated cytotoxicity | 7 | 0.000000 | BRAF,ITGAL,ITGB2,ICAM1,PIK3CA,PIK3CB,PRKCA |
| Melanoma | 6 | 0.000001 | BRAF,MDM2,EGFR,IGF1R,PIK3CA,PIK3CB |
| ErbB signaling pathway | 6 | 0.000002 | BRAF,EGFR,MAPK8,PIK3CA,PIK3CB,PRKCA |
| Leukocyte transendothelial migration | 6 | 0.000009 | ITGAL,ITGB2,ICAM1,PIK3CA,PIK3CB,PRKCA |
| Non-small cell lung cancer | 5 | 0.000011 | BRAF,EGFR,PIK3CA,PIK3CB,PRKCA |
| PI3K-Akt signaling pathway | 8 | 0.000015 | BCL2,MDM2,EGFR,IGF1R,PIK3CA,PIK3CB,PRKCA,VEGFA |
| VEGF signaling pathway | 5 | 0.000016 | PIK3CA,PIK3CB,PTGS2,PRKCA,VEGFA |
| Ras signaling pathway | 7 | 0.000016 | EGFR,IGF1R,MAPK8,PIK3CA,PIK3CB,PRKCA,VEGFA |
| Regulation of actin cytoskeleton | 6 | 0.000157 | BRAF,EGFR,ITGAL,ITGB2,PIK3CA,PIK3CB |